GSK taps recruiter for director search; Novartis unveils positive data on Ilaris;

 @FiercePharma. Bayer boosts liquid assets to weather euro crisis, including unpaid bills from Italy, Spain, Portugal. News | Follow @FiercePharma

> GlaxoSmithKline ($GSK) has hired an executive search firm to identify two new non-executive directors to replace board members likely to retire next May, in a move that may be part of a broader push to rejuvenate the company's board. Report

> As Novartis ($NVS) announced positive data on its anti-inflammatory drug Ilaris, Barron's asks why investors appear to be overlooking the Swiss drugmaker, given its new products and pipeline candidates. News | Story

> Pozen Pharmaceuticals ($POZN) isn't happy with sales of its arthritis combo drug Vimovo, so it's working with marketing partner AstraZeneca ($AZN) to determine how to boost the numbers. Report

> India's Lupin challenged the government's maximum retail price fixed for several of its drugs as the country expands its price-controls program. Piece

> Gilead Sciences ($GILD) said new data showed its antiretroviral drug Viread suppressed the hepatitis B virus and reduced liver fibrosis and cirrhosis in patients with the disease. More

> AMAG Pharmaceuticals CEO Brian Pereira resigned as the company announced plans to cut one-quarter of its staff and consider putting itself on the block. News

> Sri Lanka is gathering data to implement a new pricing program that would set maximum retail prices on all medicines. Story

> AstraZeneca ($AZN) agreed to a $60 million cancer-drug supply partnership with the Algerian drugmaker Biopharm. Report

Biotech News

 @FierceBiotech: Sanofi sharpening budget ax in ongoing R&D restructuring effort. News | Follow @FierceBiotech

 @JohnCFierce: Nabi has now proved conclusively that NicVAX is worthless. Second PhIII data batch bad as the the first. Release | Follow @JohnCFierce

 @RyanMFierce: Speaking of Karate Kid, I think this was the FDA's crane kick in the face of its critics: Item | Follow @RyanMFierce

> NPS wraps another positive PhIII study as parathyroid drug impresses. News

> Sanofi sharpening budget ax in ongoing R&D restructuring effort. Article

> Ex-Genzyme CEO Termeer, GE back translational tech with $20M round. Story

Medical Devices News

> Could BD be ripe for pick-up? More

> Termeer participates in $20M round for NanoString. Piece

> IntraPace gets CE Mark for new abiliti lead. News

> J&J unit completes SterilMed buy. Story

Biotech IT News

> Pfizer to pay big bucks for scouring databases for trials subjects. Article

> Selventa and Linguamatics team on mining details in journals. Item

> Scientists building 'computer operating system' for synthetic biology. More

And Finally... A sixteenfold increase in reflux-drug scripts for infants is probably unnecessary, experts say. Item

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.